Home LiteratureArticle Details
PMID: 21786187 Published · ppublish English Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk.

Journal of cardiovascular translational research ·Vol. 4 ·No. 6 ·2011-12-00 ·Pages 811-22

Jayachandran M, Litwiller RD, Lahr BD, Bailey KR, Owen WG, Mulvagh SL, Heit JA, Hodis HN, Harman SM, Miller VM

Abstract

A woman's risk for metabolic syndrome (MS) increases at menopause, with an associated increase in risk for cardiovascular disease. We hypothesized that early menopause-related changes in platelet activity and concentrations of microvesicles derived from activated blood and vascular cells provide a mechanistic link to the early atherothrombotic process. Thus, platelet functions and cellular origin of blood-borne microvesicles in recently menopausal women (n = 118) enrolled in the Kronos Early Estrogen Prevention Study were correlated with components of MS and noninvasive measures of cardiovascular disease [carotid artery intima medial thickness (CIMT), coronary artery calcium (CAC) score, and endothelial reactive hyperemic index (RHI)]. Specific to individual components of the MS pentad, platelet number increased with increasing waist circumference, and platelet secretion of ATP and expression of P-selectin decreased with increasing blood glucose (p = 0.005) and blood pressure (p < 0.05), respectively. Waist circumference and systolic blood pressure were independently associated with monocyte- and endothelium-derived microvesicles (p < 0.05). Platelet-derived and total procoagulant phosphatidylserine-positive microvesicles, and systolic blood pressure correlated with CIMT (p < 0.05), but not with CAC or RHI. In summary, among recently menopausal women, specific platelet functions and concentrations of circulating activated cell membrane-derived procoagulant microvesicles change with individual components of MS. These cellular changes may explain in part how menopause contributes to MS and, eventually, to cardiovascular disease.

MeSH Terms
Adenosine Triphosphate/blood Adult Atherosclerosis/blood,etiology,pathology,physiopathology,prevention & control Biomarkers/blood Blood Glucose/analysis Blood Platelets/metabolism Blood Pressure Calcium/metabolism Carotid Arteries/pathology Cell-Derived Microparticles/metabolism Coronary Vessels/metabolism Double-Blind Method Endothelium, Vascular/physiopathology Estrogen Replacement Therapy Female Humans Menopause/blood Metabolic Syndrome/blood,etiology,pathology,physiopathology Middle Aged Multivariate Analysis P-Selectin/blood Platelet Function Tests Regression Analysis Risk Assessment Risk Factors Waist Circumference
Chemicals
Biomarkers Blood Glucose P-Selectin SELP protein, human Adenosine Triphosphate Calcium
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Jayachandran Muthuvel
Department of Physiology & Biomedical Engineering, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Litwiller Robert D
Lahr Brian D
Bailey Kent R
Owen Whyte G
Mulvagh Sharon L
Heit John A
Hodis Howard N
Harman S Mitchell
Miller Virginia M
References (53)
53 references, click to expand
  1. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome.
    Am J Pathol. 2008 Oct;173(4):1210-9 PMID: 18772329
  2. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin.
    Circulation. 1994 Dec;90(6):2671-8 PMID: 7994807
  3. Shedding microvesicles: artefacts no more.
    Trends Cell Biol. 2009 Feb;19(2):43-51 PMID: 19144520
  4. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression.
    Menopause. 2007 May-Jun;14(3 Pt 1):373-84 PMID: 17438515
  5. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.
    Thromb Haemost. 2003 Jul;90(1):124-31 PMID: 12876635
  6. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.
    J Infect Dis. 2011 Feb 15;203(4):452-63 PMID: 21220772
  7. Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility.
    Transfusion. 2003 Mar;43(3):328-34 PMID: 12675717
  8. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
    Circulation. 2007 Feb 20;115(7):840-5 PMID: 17309934
  9. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial.
    Menopause. 2005 Jul-Aug;12(4):366-73 PMID: 16037751
  10. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
    Lancet. 2003 Aug 9;362(9382):428-32 PMID: 12927428
  11. Estrogen, inflammation, and platelet phenotype.
    Gend Med. 2008;5 Suppl A:S91-S102 PMID: 18395686
  12. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.
    N Engl J Med. 2003 Aug 7;349(6):535-45 PMID: 12904518
  13. KEEPS: The Kronos Early Estrogen Prevention Study.
    Climacteric. 2005 Mar;8(1):3-12 PMID: 15804727
  14. Platelet dysfunction in central obesity.
    Nutr Metab Cardiovasc Dis. 2009 Jul;19(6):440-9 PMID: 19346117
  15. Circulating microparticles: pathophysiology and clinical implications.
    Blood Rev. 2007 May;21(3):157-71 PMID: 17118501
  16. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause.
    Fertil Steril. 2004 Aug;82(2):391-7 PMID: 15302289
  17. Platelet responses to compound interactions with thrombin.
    Biochemistry. 1999 Jul 13;38(28):8936-47 PMID: 10413467
  18. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.
    Ann Intern Med. 2001 Dec 4;135(11):939-53 PMID: 11730394
  19. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
    Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8 PMID: 9409295
  20. Formation of prostacyclin-sensitive platelet aggregates in human whole blood in vitro. Part II. The occurrence of the phenomenon in males suffering from acute myocardial infarction.
    Scand J Clin Lab Invest. 1987 Apr;47(2):125-30 PMID: 3554489
  21. Cell biology of atherosclerosis.
    Annu Rev Physiol. 1995;57:791-804 PMID: 7778883
  22. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.
    Circulation. 2002 Feb 19;105(7):804-9 PMID: 11854119
  23. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.
    Circulation. 2004 Jan 6;109(1):42-6 PMID: 14676144
  24. Calcium signaling in human platelets.
    Annu Rev Physiol. 1990;52:431-49 PMID: 2158766
  25. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.
    Diabetes Obes Metab. 2006 Sep;8(5):538-54 PMID: 16918589
  26. The role of carotid arterial intima-media thickness in predicting clinical coronary events.
    Ann Intern Med. 1998 Feb 15;128(4):262-9 PMID: 9471928
  27. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress.
    Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):665-71 PMID: 20399083
  28. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?
    J Am Coll Cardiol. 2009 Dec 15;54(25):2366-73 PMID: 20082925
  29. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women.
    J Clin Endocrinol Metab. 2001 Aug;86(8):3629-34 PMID: 11502788
  30. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal.
    Arterioscler Thromb. 1994 Feb;14(2):177-92 PMID: 8305407
  31. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.
    Circulation. 2011 Mar 22;123(11):1243-62 PMID: 21325087
  32. Potential role of platelet FcgammaRIIA in collagen-mediated platelet activation associated with atherothrombosis.
    Atherosclerosis. 2002 Oct;164(2):261-7 PMID: 12204796
  33. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial.
    Menopause. 2005 Nov-Dec;12(6):728-33 PMID: 16278616
  34. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia.
    J Am Coll Cardiol. 2004 Dec 7;44(11):2137-41 PMID: 15582310
  35. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?
    Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):972-8 PMID: 10195925
  36. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study.
    Circulation. 2008 May 13;117(19):2467-74 PMID: 18458169
  37. Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
    Thromb Haemost. 1976 Jun 30;35(3):702-11 PMID: 989974
  38. Postmenopausal hormone therapy and cardiovascular disease in perspective.
    Clin Obstet Gynecol. 2008 Sep;51(3):564-80 PMID: 18677151
  39. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques.
    J Am Coll Cardiol. 2007 Feb 20;49(7):772-7 PMID: 17306706
  40. Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis.
    Am J Cardiol. 2002 Jun 20;89(12A):19E-27E; discussion 27E PMID: 12084399
  41. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
    JAMA. 2001 May 16;285(19):2486-97 PMID: 11368702
  42. Endothelial function and cardiovascular risk stratification in menopausal women.
    Climacteric. 2010 Feb;13(1):45-54 PMID: 19657788
  43. Platelet hyperreactivity in women from families with premature atherosclerosis.
    J Am Med Womens Assoc (1972). 2003 Fall;58(4):272-7 PMID: 14640259
  44. Platelet characteristics associated with coronary artery disease.
    J Thromb Haemost. 2003 Jun;1(6):1296-303 PMID: 12871333
  45. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins.
    Atherosclerosis. 2006 Nov;189(1):76-82 PMID: 16386257
  46. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.
    Diabet Med. 2006 May;23(5):469-80 PMID: 16681555
  47. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
    Circulation. 2005 Oct 25;112(17):2735-52 PMID: 16157765
  48. Platelet activation, inflammatory mediators and hypercholesterolemia.
    Curr Vasc Pharmacol. 2003 Jun;1(2):157-69 PMID: 15320841
  49. Gender differences in the metabolic syndrome and their role for cardiovascular disease.
    Clin Res Cardiol. 2006 Mar;95(3):136-47 PMID: 16598526
  50. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women.
    Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H931-H938 PMID: 18621859
  51. Interleukin-6 and megakaryocytopoiesis: an update.
    Ann Hematol. 1996 Oct;73(4):157-62 PMID: 8890702
  52. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
    J Cardiovasc Transl Res. 2009 Sep;2(3):228-39 PMID: 19668346
  53. Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1819-23 PMID: 8446595
Article Info
Journal
Journal of cardiovascular translational research
Abbr.
J Cardiovasc Transl Res
ISSN
1937-5395
Published
2011-12-00
Epub
2011-00-24
Pages
811-22
Language
English
Region
United States
NLM ID
101468585
PMCID
PMC3219869
Subset
IM
Grants
NCRR NIH HHS · UL1 RR024150-05 · United States
NHLBI NIH HHS · HL90639 · United States
NHLBI NIH HHS · R01 HL090639-04 · United States
NCRR NIH HHS · 1UL1 RR024150 · United States
NCRR NIH HHS · UL1 RR024150 · United States
NHLBI NIH HHS · R01 HL090639 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com